165 related articles for article (PubMed ID: 15789774)
1. [VIOXX written off--and what next? COX-2 inhibitors and cardiovascular diseases].
Jerie P
Cas Lek Cesk; 2005; 144(1):4. PubMed ID: 15789774
[No Abstract] [Full Text] [Related]
2. Discontinuation of Vioxx.
Nutt DJ
Lancet; 2005 Jan 1-7; 365(9453):28. PubMed ID: 15639676
[No Abstract] [Full Text] [Related]
3. [The rise and fall of Vioxx: society, values and their choice].
Caspi D
Harefuah; 2004 Nov; 143(11):770-1. PubMed ID: 15603261
[No Abstract] [Full Text] [Related]
4. COX-2 inhibitors and cardiovascular toxicity: a class effect?
Laible B
S D J Med; 2005 Mar; 58(3):93-4. PubMed ID: 15794479
[No Abstract] [Full Text] [Related]
5. COX-2 inhibitors and hypercoagulability.
Farkouh ME
Clin Adv Hematol Oncol; 2005 Jan; 3(1):35-6. PubMed ID: 16166966
[No Abstract] [Full Text] [Related]
6. [Really only Vioxx?].
Heinzl S
Med Monatsschr Pharm; 2004 Nov; 27(11):361. PubMed ID: 15566229
[No Abstract] [Full Text] [Related]
7. [Cardiovascular risks of Cox-2-antagonists. Opinion on the marketed name rofecoxib, and its market-withdrawn valdecoxib and the actual therapeutic restrictions].
Bolten WW; Reiter S;
Z Rheumatol; 2005 May; 64(4):286-9. PubMed ID: 15909092
[No Abstract] [Full Text] [Related]
8. Cardiovascular safety of rofecoxib (Vioxx): lessons learned and unanswered questions: we need processes in place to follow up suspicions about serious adverse events.
Langton PE; Hankey GJ; Eikelboom JW
Med J Aust; 2004 Nov; 181(10):524-5. PubMed ID: 15540956
[No Abstract] [Full Text] [Related]
9. Health Canada lukewarm on Vioxx panel findings.
Murray S
CMAJ; 2005 Aug; 173(4):350. PubMed ID: 16103502
[No Abstract] [Full Text] [Related]
10. Rofecoxib (Vioxx) withdrawal: do product monographs adequately inform physicians?
Can Fam Physician; 2005 Feb; 51(2):212-3. PubMed ID: 15751564
[No Abstract] [Full Text] [Related]
11. Learning the value of drugs--is rofecoxib a regulatory success story?
Eisenberg RS
N Engl J Med; 2005 Mar; 352(13):1285-7. PubMed ID: 15800222
[No Abstract] [Full Text] [Related]
12. Increased risk of cardiovascular events with coxibs and NSAIDs.
Scott DG; Watts RA
Lancet; 2005 Apr 30-May 6; 365(9470):1537. PubMed ID: 15866299
[No Abstract] [Full Text] [Related]
13. The Vioxx debacle revisited.
Daikh DI
Am J Med; 2005 Sep; 118(9):1057. PubMed ID: 16164908
[No Abstract] [Full Text] [Related]
14. Balancing risks and benefits in pain medicine: wither Vioxx.
Gallagher RM
Pain Med; 2004 Dec; 5(4):329-30. PubMed ID: 15563316
[No Abstract] [Full Text] [Related]
15. Cardiovascular complications of COX2 selective inhibitors cause considerable concern.
Hedner T; Himmelmann A
Blood Press; 2004; 13(5):260-1. PubMed ID: 15545147
[No Abstract] [Full Text] [Related]
16. The Vioxx debacle revisited.
Manthous CA
Am J Med; 2005 Sep; 118(9):1056-7; author reply 1057. PubMed ID: 16164904
[No Abstract] [Full Text] [Related]
17. Vioxx doctors wooed by Merck are now its foes.
Tesoriero HW
Wall St J (East Ed); 2006 Mar; ():B1, B3. PubMed ID: 16578911
[No Abstract] [Full Text] [Related]
18. [General practice study of therapy of acute pain. Patients prefer cox-2 inhibitors].
MMW Fortschr Med; 2004 May; 146(21):61. PubMed ID: 15373091
[No Abstract] [Full Text] [Related]
19. Don't throw out the baby with the bathwater!
Kamen B; Kieran M
J Pediatr Hematol Oncol; 2005 Feb; 27(2):59-60. PubMed ID: 15701976
[No Abstract] [Full Text] [Related]
20. Drug safety. FDA panel urges caution on many anti-inflammatory drugs.
Couzin J
Science; 2005 Feb; 307(5713):1183-5. PubMed ID: 15731414
[No Abstract] [Full Text] [Related]
[Next] [New Search]
